Holen Sie sich die Stockscreener-App
6.88
5.52%
0.36
Handel nachbörslich:
6.88
Schlusskurs vom Vortag:
$6.52
Offen:
$6.54
24-Stunden-Volumen:
431.75K
Relative Volume:
0.67
Marktkapitalisierung:
$372.15M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.3544
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+3.46%
1M Leistung:
-1.15%
6M Leistung:
+110.40%
1J Leistung:
-16.61%
1-Tages-Spanne:
$6.35
$7.01
1-Wochen-Bereich:
$6.35
$7.01
52-Wochen-Spanne:
$2.315
$9.30
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.88 | 346.73M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics at Cantor Global Healthcare Conference: Renewed Hope in Sickle Cell - Investing.com
What’s Fulcrum Therapeutics Inc.’s historical return2025 Market WrapUp & Long Hold Capital Preservation Plans - khodrobank.com
Chart overlay techniques for tracking Fulcrum Therapeutics Inc.2025 Geopolitical Influence & Accurate Buy Signal Alerts - Newser
Fulcrum Therapeutics Inc. stock daily chart insightsCPI Data & Fast Gaining Stock Strategy Reports - Newser
Is Fulcrum Therapeutics Inc. stock reversal real or fakeJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
Relative strength of Fulcrum Therapeutics Inc. in sector analysis2025 Price Targets & Weekly High Momentum Picks - Newser
Does Fulcrum Therapeutics Inc. qualify in momentum factor screening2025 Dividend Review & Risk Controlled Daily Trade Plans - Newser
Will Fulcrum Therapeutics Inc. outperform during market ralliesJuly 2025 Levels & Fast Gain Swing Trade Alerts - khodrobank.com
What institutional flow reveals about Fulcrum Therapeutics Inc.July 2025 Sentiment & Verified Momentum Watchlists - Newser
What’s the recovery path for long term holders of Fulcrum Therapeutics Inc.July 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - Newser
How sentiment analysis helps forecast Fulcrum Therapeutics Inc.Portfolio Gains Summary & Expert Curated Trade Setups - Newser
Will Fulcrum Therapeutics Inc. see short term momentumMarket Trend Review & Free Daily Entry Point Trade Alerts - Newser
Does Fulcrum Therapeutics Inc. show high probability of reboundJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Sector ETF performance correlation with Fulcrum Therapeutics Inc.Weekly Profit Summary & Consistent Income Trade Ideas - Newser
Custom watchlist performance reports with Fulcrum Therapeutics Inc.Portfolio Update Report & High Yield Stock Recommendations - Newser
Exit strategy if you’re trapped in Fulcrum Therapeutics Inc.July 2025 Market Mood & Low Risk High Reward Trade Ideas - Newser
Fulcrum Therapeutics Inc. stock prediction for this weekPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
How high can Fulcrum Therapeutics Inc. stock goJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Technical Models Suggest Fulcrum Therapeutics Inc. May Rebound Soon2025 Sector Review & Daily Growth Stock Investment Tips - beatles.ru
What institutional flow reveals about Fulcrum Therapeutics IncEarnings Trend Report & Precise Swing Trade Entry Alerts - Newser
Market reaction to Fulcrum Therapeutics Inc.’s recent newsQuarterly Performance Summary & Accurate Technical Buy Alerts - Newser
Is Fulcrum Therapeutics Inc. vulnerable to short sellers2025 AllTime Highs & Reliable Volume Spike Trade Alerts - khodrobank.com
Will Fulcrum Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
Strategies to average down on Fulcrum Therapeutics Inc.Weekly Gains Report & Verified Momentum Stock Alerts - Newser
Combining machine learning predictions for Fulcrum Therapeutics Inc.Market Movers & Fast Entry High Yield Tips - Newser
What is the dividend yield of Fulcrum Therapeutics Inc.July 2025 Intraday Action & Consistent Profit Focused Trading Strategies - khodrobank.com
Can Fulcrum Therapeutics Inc. weather a recessionTrade Risk Summary & Verified Momentum Watchlists - khodrobank.com
Will Fulcrum Therapeutics Inc. outperform tech stocksEarnings Summary Report & Weekly Sector Rotation Insights - khodrobank.com
Will earnings trigger a reversal in Fulcrum Therapeutics Inc.2025 Fundamental Recap & Daily Volume Surge Trade Alerts - Newser
Is this a good reentry point in Fulcrum Therapeutics Inc.July 2025 Intraday Action & Accurate Trade Setup Notifications - Newser
Using Bollinger Bands to evaluate Fulcrum Therapeutics Inc.July 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Is Fulcrum Therapeutics Inc. in a bullish channelQuarterly Investment Review & High Conviction Trade Alerts - khodrobank.com
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Weekly Risk Report & High Conviction Trade Alerts - Newser
Is Fulcrum Therapeutics Inc. reversing from oversold territoryCPI Data & Reliable Breakout Forecasts - Newser
Will Fulcrum Therapeutics Inc. benefit from macro trends2025 Institutional Moves & Long Hold Capital Preservation Plans - Newser
Risk vs reward if holding onto Fulcrum Therapeutics Inc.Earnings Summary Report & Detailed Earnings Play Alerts - Newser
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):